Amicus Therapeutics, Inc.

NasdaqGM:FOLD Stock Report

Market Cap: US$2.9b

Amicus Therapeutics Management

Management criteria checks 4/4

Amicus Therapeutics' CEO is Brad Campbell, appointed in Jan 2015, has a tenure of 9.92 years. total yearly compensation is $8.20M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth $8.69M. The average tenure of the management team and the board of directors is 7.8 years and 6.4 years respectively.

Key information

Brad Campbell

Chief executive officer

US$8.2m

Total compensation

CEO salary percentage8.5%
CEO tenure9.9yrs
CEO ownership0.3%
Management average tenure7.8yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden

Nov 10
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden

Amicus: Teva Settlement Clears Revenue Path Forward For Galafold

Oct 18

'Boring' Amicus Therapeutics Is Making Progress

Sep 29

Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector

Aug 16

Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Jul 02
Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Jun 06
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Amicus Therapeutics: Too Cheap At Under $10 A Share

May 20

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Mar 27
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Amicus Therapeutics: Expect Improved Commercial Momentum In 2024

Feb 29

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk

Dec 19
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Jul 06
Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

May 14
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

Mar 23
Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Dec 06
We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Aug 25
Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding

Aug 10

Amicus Therapeutics Q2 2022 Earnings Preview

Aug 03

CEO Compensation Analysis

How has Brad Campbell's remuneration changed compared to Amicus Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$105m

Jun 30 2024n/an/a

-US$120m

Mar 31 2024n/an/a

-US$147m

Dec 31 2023US$8mUS$699k

-US$152m

Sep 30 2023n/an/a

-US$174m

Jun 30 2023n/an/a

-US$185m

Mar 31 2023n/an/a

-US$204m

Dec 31 2022US$9mUS$591k

-US$237m

Sep 30 2022n/an/a

-US$264m

Jun 30 2022n/an/a

-US$281m

Mar 31 2022n/an/a

-US$270m

Dec 31 2021US$5mUS$551k

-US$250m

Sep 30 2021n/an/a

-US$239m

Jun 30 2021n/an/a

-US$252m

Mar 31 2021n/an/a

-US$254m

Dec 31 2020US$5mUS$516k

-US$277m

Sep 30 2020n/an/a

-US$295m

Jun 30 2020n/an/a

-US$293m

Mar 31 2020n/an/a

-US$325m

Dec 31 2019US$4mUS$501k

-US$356m

Sep 30 2019n/an/a

-US$345m

Jun 30 2019n/an/a

-US$442m

Mar 31 2019n/an/a

-US$419m

Dec 31 2018US$3mUS$468k

-US$349m

Sep 30 2018n/an/a

-US$340m

Jun 30 2018n/an/a

-US$293m

Mar 31 2018n/an/a

-US$279m

Dec 31 2017US$2mUS$450k

-US$284m

Compensation vs Market: Brad's total compensation ($USD8.20M) is about average for companies of similar size in the US market ($USD6.65M).

Compensation vs Earnings: Brad's compensation has been consistent with company performance over the past year.

CEO

Brad Campbell (48 yo)

9.9yrs

Tenure

US$8,202,366

Compensation

Mr. Bradley L. Campbell, also known as Brad, MBA, serves as Director of Gennao Bio, Inc. since March 2022. He serves as Director of Alliance for Regenerative Medicine. He served as Chief Operating Officer...

Leadership Team

NamePositionTenureCompensationOwnership
Bradley Campbell
CEO, President & Director9.9yrsUS$8.20m0.30%
$ 8.7m
Simon Nicolas Harford
Chief Financial Officer1.3yrsUS$3.27m0.0048%
$ 139.4k
Ellen Rosenberg
Chief Legal Officer & Corporate Secretary8.8yrsUS$4.08m0.064%
$ 1.9m
David Clark
Chief People Officer6.2yrsUS$3.21m0.046%
$ 1.4m
Jeffrey Castelli
Chief Development Officerno dataUS$3.67m0.080%
$ 2.3m
Samantha Prout
Chief Accounting Officer & Controller6.8yrsno data0.025%
$ 724.5k
Jill Weimer
Chief Science Officerno datano datano data
Andrew Faughnan
Senior Director of Investor Relationsno datano datano data
Patrik Florencio
Global Chief Compliance & Risk Officer9.3yrsno datano data
Diana Moore
Head of Global Corporate Communicationsno datano datano data
Jayne Gershkowitz
Chief Patient Advocate9.3yrsno datano data
Julie Yu
Chief Program Officer4.6yrsno datano data

7.8yrs

Average Tenure

54.5yo

Average Age

Experienced Management: FOLD's management team is seasoned and experienced (7.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bradley Campbell
CEO, President & Director6.5yrsUS$8.20m0.30%
$ 8.7m
Burke Whitman
Independent Director5.5yrsUS$391.25k0.026%
$ 761.9k
Michael Kelly
Independent Director4yrsUS$391.25k0.0098%
$ 288.1k
Glenn Sblendorio
Independent Director18.5yrsUS$407.07k0.025%
$ 735.0k
Margaret McGlynn
Independent Director15.2yrsUS$401.25k0.017%
$ 496.9k
Michael Raab
Chairman & Lead Independent Director20.9yrsUS$426.25k0.025%
$ 735.0k
Eiry Roberts
Independent Director3.5yrsUS$390.00k0.0080%
$ 235.7k
Lynn Bleil
Independent Director6.3yrsUS$397.50k0.024%
$ 716.3k

6.4yrs

Average Tenure

63yo

Average Age

Experienced Board: FOLD's board of directors are considered experienced (6.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:02
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amicus Therapeutics, Inc. is covered by 29 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Michael UlzBaird
Yun ZhongBerenberg